Akari Therapeutics PLC • AKTX

Capital at risk.

About Akari Therapeutics PLC
Ticker
info
AKTX
Trading on
info
NASDAQ
ISIN
info
US00972G1085
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Dr. Samir Rashmikant Patel M.D.
Headquarters
info
22 Boston Wharf Road, Boston, MA, United States, 02210
Employees
info
9
Website
info
akaritx.com
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Metrics
BasicAdvanced
Market cap
info
$30.3M
P/E ratio
info
-
EPS
info
-$2.58
Dividend Yield
info
0.00%
Beta
info
0.95
Forward P/E ratio
info
0
EBIDTA
info
$-18.1M
Ex dividend date
info
-
Price & volume
Market cap
info
$30.3M
Average daily volume
info
0M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
0
Trailing P/E
info
0
Price to sales
info
0
Price to book
info
3.07
Earnings
EPS
info
-$2.58
EPS estimate (current quarter)
info
$0.00
EPS estimate (next quarter)
info
$0.00
EBITDA
info
$-18.1M
Revenues (TTM)
info
$0M
Revenues per share (TTM)
info
$0.00
Technicals
Beta
info
0.95
52-week High
info
$4.40
52-week Low
info
$0.85
50-day moving average
info
$2.67
200-day moving average
info
$2.55
Short ratio
info
1.92
Short %
info
0.23%
Management effectiveness
ROE (TTM)
info
1,281.43%
ROA (TTM)
info
172.83%
Profit margin
info
0.00%
Gross profit margin
info
$0M
Operating margin
info
0.00%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
0.00%
Share stats
Outstanding Shares
info
20.6M
Float
info
10.5B
Insiders %
info
11.91%
Institutions %
info
0.51%
Analyst Insights & forecasts
info

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

info
$80.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-
-$1.20
100.00%
Q2 • 23Beat
-
-$0.60
100.00%
Q3 • 23Beat
-$0.83
-
-
Q1 • 24Beat
-$0.80
-
-
Q2 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0M
$-7.6M
∞%
Q2 • 24
$0M
$-2.9M
∞%
Q3 • 24
NaN%
61.70%
NaN%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$5.1M
$8.8M
172.95%
Q2 • 24
$2.7M
$9.4M
344.84%
Q3 • 24
46.14%
7.39%
99.39%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-4.9M
-
$7.8M
$-4.9M
Q2 • 24
$-1.5M
-
$-0.4M
$-1.5M
Q3 • 24
69.55%
-
105.71%
69.55%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Akari Therapeutics PLC share?
Collapse

Akari Therapeutics PLC shares are currently traded for undefined per share.

How many shares does Akari Therapeutics PLC have?
Collapse

Akari Therapeutics PLC currently has 20.6M shares.

Does Akari Therapeutics PLC pay dividends?
Collapse

No, Akari Therapeutics PLC doesn't pay dividends.

What is Akari Therapeutics PLC 52 week high?
Collapse

Akari Therapeutics PLC 52 week high is $4.40.

What is Akari Therapeutics PLC 52 week low?
Collapse

Akari Therapeutics PLC 52 week low is $0.85.

What is the 200-day moving average of Akari Therapeutics PLC?
Collapse

Akari Therapeutics PLC 200-day moving average is $2.55.

Who is Akari Therapeutics PLC CEO?
Collapse

The CEO of Akari Therapeutics PLC is Dr. Samir Rashmikant Patel M.D..

How many employees Akari Therapeutics PLC has?
Collapse

Akari Therapeutics PLC has 9 employees.

What is the market cap of Akari Therapeutics PLC?
Collapse

The market cap of Akari Therapeutics PLC is $30.3M.

What is the P/E of Akari Therapeutics PLC?
Collapse

The current P/E of Akari Therapeutics PLC is null.

What is the EPS of Akari Therapeutics PLC?
Collapse

The EPS of Akari Therapeutics PLC is -$2.58.

What is the PEG Ratio of Akari Therapeutics PLC?
Collapse

The PEG Ratio of Akari Therapeutics PLC is 0.

What do analysts say about Akari Therapeutics PLC?
Collapse

According to the analysts Akari Therapeutics PLC is considered a buy.